Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including ...

Recognized in the Healthcare category of the 2025 Top Innovations contest, Haystack MRD® enables minimal residual disease ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Natera Inc. (($NTRA)) announced an update on their ongoing clinical study. Natera Inc. has initiated a new clinical study titled ‘Signatera-Guided ...

Personalis ((PSNL)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data ...

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

A major international study has found that a simple blood test may help doctors decide which patients with stage 3 colon ...

In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo.

A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of ...

From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...